Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression

Cell Reports

Volumn 14, Issue 7, 2016, Pages 1748-1760

  Galletti, Giovanni ^a,b   Scielzo, Cristina ^a,b   Barbaglio, Federica ^a   Rodriguez, Tania Véliz ^a   Riba, Michela ^a   Lazarevic, Dejan ^a   Cittaro, Davide ^a   Simonetti, Giorgia ^c   Ranghetti, Pamela ^a   Scarfò, Lydia ^a   Ponzoni, Maurilio ^a   Rocchi, Martina ^a   Corti, Angelo ^a   Anselmo, Achille ^d   van Rooijen, Nico ^e   Klein, Christian ^f   Ries, Carola H ^g   Ghia, Paolo ^a,b   De Palma, Michele ^a,h   Caligaris Cappio, Federico ^a,b   Bertilaccio, Maria Teresa Sabrina ^a,b   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Roche Pharmaceutical Research and Early Development Oncology Discovery and Translational Area Roche Innovation Center Zurich   (Switzerland)

^g ROCHE INNOVATION CENTER MUNICH   (Germany)

^h EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CLODRONIC ACID; CSF1R PROTEIN, MOUSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; LIPOSOME; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL INTERACTION; CELL KILLING; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEPLETION; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CANCER TRANSPLANTATION; CELL COMMUNICATION; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; PATHOLOGY; PRIMARY CELL CULTURE; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; B-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE, TUMOR; CLODRONIC ACID; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPOSOMES; MACROPHAGES; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PRIMARY CELL CULTURE; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84959158011     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.01.042     Document Type: Article

References (47)

1. Acquati F., Bertilaccio S., Grimaldi A., Monti L., Cinquetti R., Bonetti P., Lualdi M., Vidalino L., Fabbri M., Sacco M.G., et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc. Natl. Acad. Sci. USA 2011, 108:1104-1109.
2. Acquati F., Lualdi M., Bertilaccio S., Monti L., Turconi G., Fabbri M., Grimaldi A., Anselmo A., Inforzato A., Collotta A., et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 2013, 110:8140-8145.
3. Arruga F., Gizdic B., Serra S., Vaisitti T., Ciardullo C., Coscia M., Laurenti L., D'Arena G., Jaksic O., Inghirami G., et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2014, 28:1060-1070.
4. Batista F.D., Harwood N.E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 2009, 9:15-27.
5. Beldjord K., Chevret S., Asnafi V., Huguet F., Boulland M.L., Leguay T., Thomas X., Cayuela J.M., Grardel N., Chalandon Y., et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014, 123:3739-3749. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).
6. Bertilaccio M.T., Scielzo C., Simonetti G., Ponzoni M., Apollonio B., Fazi C., Scarfò L., Rocchi M., Muzio M., Caligaris-Cappio F., Ghia P. A novel Rag2-/-gammac-/--xenograft model of human CLL. Blood 2010, 115:1605-1609.
7. Bichi R., Shinton S.A., Martin E.S., Koval A., Calin G.A., Cesari R., Russo G., Hardy R.R., Croce C.M. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. USA 2002, 99:6955-6960.
8. Burger J.A., Gribben J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 2014, 24:71-81.
9. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
10. Burger J.A., Quiroga M.P., Hartmann E., Bürkle A., Wierda W.G., Keating M.J., Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
11. Bürkle A., Niedermeier M., Schmitt-Gräff A., Wierda W.G., Keating M.J., Burger J.A. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007, 110:3316-3325.
12. Burnett S.H., Kershen E.J., Zhang J., Zeng L., Straley S.C., Kaplan A.M., Cohen D.A. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J. Leukoc. Biol. 2004, 75:612-623.
13. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., Grant B., Sharman J.P., Coleman M., Wierda W.G., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013, 369:32-42.
14. Caligaris-Cappio F., Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. J. Clin. Oncol. 2008, 26:4497-4503.
15. Caligaris-Cappio F., Bertilaccio M.T., Scielzo C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin. Cancer Biol. 2014, 24:43-48.
16. Cortese D., Sutton L.A., Cahill N., Smedby K.E., Geisler C., Gunnarsson R., Juliusson G., Mansouri L., Rosenquist R. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 2014, 28:710-713.
17. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
18. Deeg H.J., Gotlib J., Beckham C., Dugan K., Holmberg L., Schubert M., Appelbaum F., Greenberg P. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002, 16:162-164.
19. Digel W., Schöniger W., Stefanic M., Janssen H., Buck C., Schmid M., Raghavachar A., Porzsolt F. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 1990, 76:1607-1613.
20. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 2011, 208:1389-1401.
21. Filip A.A., Ciseł B., Koczkodaj D., Wasik-Szczepanek E., Piersiak T., Dmoszyńska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?. Blood Cells Mol. Dis. 2013, 50:263-270.
22. Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., Erba E., Uboldi S., Zucchetti M., Pasqualini F., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
23. Hao N.B., Lü M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012:948098.
24. Herishanu Y., Pérez-Galán P., Liu D., Biancotto A., Pittaluga S., Vire B., Gibellini F., Njuguna N., Lee E., Stennett L., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
25. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., Flynn J., Jones J., Blum K.A., Buggy J.J., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
26. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., Shibuya M., Akira S., Aburatani H., Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
27. Hope C., Ollar S.J., Heninger E., Hebron E., Jensen J.L., Kim J., Maroulakou I., Miyamoto S., Leith C., Yang D.T., et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 2014, 123:3305-3315.
28. Joza N., Pospisilik J.A., Hangen E., Hanada T., Modjtahedi N., Penninger J.M., Kroemer G. AIF: not just an apoptosis-inducing factor. Ann. N Y Acad. Sci. 2009, 1171:2-11.
29. Laprevotte E., Voisin G., Ysebaert L., Klein C., Daugrois C., Laurent G., Fournie J.J., Quillet-Mary A. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J. Immunol. 2013, 191:3634-3640.
30. Leupin N., Cenni B., Novak U., Hügli B., Graber H.U., Tobler A., Fey M.F. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL). Br. J. Haematol. 2003, 121:97-100.
31. Lutzny G., Kocher T., Schmidt-Supprian M., Rudelius M., Klein-Hitpass L., Finch A.J., Dürig J., Wagner M., Haferlach C., Kohlmann A., et al. Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23:77-92.
32. MacDonald K.P., Palmer J.S., Cronau S., Seppanen E., Olver S., Raffelt N.C., Kuns R., Pettit A.R., Clouston A., Wainwright B., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010, 116:3955-3963.
33. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
34. Mössner E., Brünker P., Moser S., Püntener U., Schmidt C., Herter S., Grau R., Gerdes C., Nopora A., van Puijenbroek E., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
35. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
36. Puente X.S., Pinyol M., Quesada V., Conde L., Ordóñez G.R., Villamor N., Escaramis G., Jares P., Beà S., González-Díaz M., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
37. Reinart N., Nguyen P.H., Boucas J., Rosen N., Kvasnicka H.M., Heukamp L., Rudolph C., Ristovska V., Velmans T., Mueller C., et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 2013, 121:812-821.
38. Ries C.H., Cannarile M.A., Hoves S., Benz J., Wartha K., Runza V., Rey-Giraud F., Pradel L.P., Feuerhake F., Klaman I., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
39. Roe J.S., Vakoc C.R. C/EBPα: critical at the origin of leukemic transformation. J. Exp. Med. 2014, 211:1-4.
40. Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., Chiaretti S., Del Giudice I., Fabbri G., Bruscaggin A., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
41. Ruffell B., Coussens L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015, 27:462-472.
42. Skarzynski M., Niemann C.U., Lee Y.S., Martyr S., Maric I., Salem D., Stetler-Stevenson M., Marti G.E., Calvo K.R., Yuan C., et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res. 2015, 22:86-95.
43. Sunderkötter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., Leenen P.J. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 2004, 172:4410-4417.
44. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of "nurselikecells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
45. van Rooijen N., Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol. Biol. 2010, 605:189-203.
46. Zanesi N., Aqeilan R., Drusco A., Kaou M., Sevignani C., Costinean S., Bortesi L., La Rocca G., Koldovsky P., Volinia S., et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res. 2006, 66:915-920.
47. Zenz T., Mertens D., Küppers R., Döhner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 2010, 10:37-50.